AstraZeneca (AZN)
(Delayed Data from NSDQ)
$78.54 USD
+0.36 (0.46%)
Updated May 24, 2024 04:00 PM ET
After-Market: $78.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Price, Consensus and EPS Surprise
AZN 78.54 +0.36(0.46%)
Will AZN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AZN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AZN
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
AZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
Why Astrazeneca (AZN) is a Great Dividend Stock Right Now
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Other News for AZN
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Wall Street Breakfast: The Week Ahead